RxDoctor Payments Data

Shawn Buki, MD

Cardiovascular Disease · Frederick, MDNPI 1104829605

Payments from drug & device makers

$3,298in general payments, 2019–2025

Across 182 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$673
  • Amgen$359
  • Abbott$252
  • Amarin Pharma, Inc.$247
  • Sanofi-aventis U.S. LLC$176
  • Novo Nordisk$169
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,298 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$636,467
Medicare patients
2,379
Services billed
8,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban795$1,068,255
XareltoRivaroxaban147$197,623
EntrestoSacubitril/Valsartan88$122,601
MultaqDronedarone Hcl55$88,000
BrilintaTicagrelor23$21,304
Repatha SureclickEvolocumab17$18,273
Praluent PenAlirocumab12$16,605
Metoprolol Succinate787$15,362
Atorvastatin Calcium1,026$15,153
Droxidopa11$15,112
Rosuvastatin Calcium443$7,502
Valsartan130$6,876
Losartan Potassium520$5,451
Dabigatran EtexilateDabigatran Etexilate Mesylate24$4,872
Carvedilol ErCarvedilol Phosphate12$4,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$1,068,255795 claims
Johnson & JohnsonXarelto$67$197,623147 claims
NovartisEntresto$673$122,60188 claims
Sanofi-aventis U.S. LLCMultaq$176$88,00055 claims
AstraZenecaBrilinta$65$21,30423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →